# A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

> **NCT06773091** · PHASE1 · RECRUITING · sponsor: **Shanghai NK Cell Technology Co., LTD** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** NK042
- **DRUG:** Fludarabine (FLU)
- **DRUG:** Cyclophosphamide (CTX)

## Key facts

- **NCT ID:** NCT06773091
- **Lead sponsor:** Shanghai NK Cell Technology Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06773091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06773091, "A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06773091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*